Loading...
Market
What will be Gilead Sciences' Biktarvy sales for full-year 2024?
3
Resolution / Starting Odds
Below $12 billion • 25%
$12 billion to $12.5 billion • 25%
$12.51 billion to $13 billion • 25%
Above $13 billion • 25%
Gilead Sciences' full-year 2024 financial report
Story
Gilead Sciences Q2: EPS $2.01, Revenue $6.95B, Raises Full-Year Outlook
Aug 12, 2024, 11:02 AM
Gilead Sciences reported its second-quarter 2024 financial results, significantly surpassing Wall Street estimates. The company achieved a revenue of $6.95 billion, exceeding the estimated $6.72 billion, marking a 5% year-over-year increase. The earnings per share (EPS) stood at $2.01, surpassing the forecasted $1.60, reflecting a 50% year-over-year growth. This performance was driven by higher product sales, particularly in HIV, liver disease, and oncology segments. Biktarvy sales reached $3.23 billion, while Veklury sales were $214 million. Additionally, Gilead raised its full-year earnings outlook, projecting adjusted EPS between $3.60 and $3.90, compared to the previous range of $3.45 to $3.85. The company's market capitalization is reported at $94 billion.
View original story
Similar markets
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
Below $45 billion • 25%
$45 billion to $45.5 billion • 25%
$45.5 billion to $46 billion • 25%
Above $46 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Below $16.10 • 25%
$16.10 to $16.60 • 25%
$16.61 to $17.10 • 25%
Above $17.10 • 25%
Below $5 billion • 25%
$5 billion to $5.5 billion • 25%
$5.5 billion to $6 billion • 25%
Above $6 billion • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%